OBJECTIVE: To examine the effect of orlistat (Xenical TM ) treatment on body composition and resting energy expenditure (REE) during a 2 y weight-reduction programme in obese Finns. SUBJECTS: Of initially 96 obese subjects who participated in the weight-reduction programme, those 72 subjects (13 men, 59 women, body mass index (BMI) 35.9 AE 3.9 kgam 2 , age 43.4 AE 6.0 y, mean AE s.d.) with the complete set of data for 2 y were included in the study. DESIGN: After a 4-week lead-in period, subjects were randomized with either orlistat 120 mg t.i.d. or placebo t.i.d. in conjunction with a mildly hypoenergetic balanced diet for 1 y. This was followed by 1 y double-blind period with the subjects within each treatment group re-assigned to receive orlistat 120 mg t.i.d. or placebo t.i.d. in conjunction with a weight maintenance diet. MEASUREMENTS: Body composition and REE were measured after an overnight fast by a bioelectrical impedance method and indirect calorimeter, respectively. The measurements were performed at the beginning and at 3, 6, 12 and 24 months. RESULTS: During the ®rst year, the orlistat-treated group had greater reduction of body weight and fat mass but not of fat-free mass or REE as compared to placebo. During the second year, orlistat treatment was associated with smaller regain of body weight and fat mass with no signi®cant differences in the changes of fat-free mass or REE as compared to placebo. CONCLUSION: In addition to better weight loss and maintenance of reduced weight, orlistat treatment is associated with bene®cial changes in body composition but with no excess decrease in resting energy expenditure as compared to that achieved during placebo with a dietary therapy alone.
Introduction
Resting energy expenditure (REE) is the major regulator of energy metabolism. Even minor changes in REE could lead to energy imbalance. 1 A low REE has been shown to predict body weight gain. 2 It may also reduce the extent of weight loss. 3 REE is greatly in¯uenced by body composition. Fat-free mass (FFM) re¯ects the amount of metabolically active tissue 4 and is the main determinant of REE, accounting for 43 ± 85% of its variation. 5, 6 The metabolic rate of body fat mass (FM) is only 1% of the metabolic rate of the most energy-demanding organs, 7 and thus the impact of FM on REE is minor as compared with FFM. Therefore, the changes in body composition and consequently in energy expenditure during weight reduction 8 could be crucial for the maintenance of reduced weight in the long term.
Energy restriction and increased physical activity are generally recommended as the ®rst line treatment of obesity. Orlistat (Xenical TM ) is a novel pancreatic lipase inhibitor promoting weight loss in obese patients. 9, 10 In conjunction with a mildly hypoenergetic balanced diet, it (120 mg t.i.d.) inhibits about 30% of the absorption of ingested fat. The speci®c effect of weight loss achieved during orlistat treatment on energy expenditure and body composition is, however, still poorly known. Therefore, the aim of the present study was to examine the effect of orlistat treatment on body composition and resting energy expenditure during a 2 y weight-reduction programme in obese Finns.
Subjects and methods

Subjects
Initially 96 obese subjects (17 men, 79 women, body mass index (BMI) 35.8AE 3.9 (29.9 ± 43.5) kgam 2 , age 43.5AE 6.3 (29 ± 57) y, mean AE s.d. (range)) participated in a 2 y, double-blind, randomized placebocontrolled weight-reduction trial in two centres (Kuopio and Helsinki) in Finland as a part of European multicentre study assessing the effect of orlistat (Xenical TM ) in long-term weight control. 11 The subjects, with BMI 30.0 ± 43.0 kgam 2 and age ! 18 y, were recruited into the study mainly from the occupational health care systems in Kuopio and Helsinki. The main exclusion criteria were known diabetes (by repeated measurements of fasting plasma glucose), signi®cant thyroid, liver or kidney disease, eating disorders, or uncontrolled hypertension (diastolic blood pressure ! 105 mmHg). The study protocol was approved by the Ethics Committees of the University Hospitals of Kuopio and Helsinki and all participants gave informed consent for the participation in the study.
Among these 96 subjects, those who withdrew from the weight-reduction programme prematurely were excluded from the present study, ie six subjects during the ®rst and eight during the second year. In addition, 10 subjects with an incomplete set of data available for the 2 y were excluded. Thus, altogether 24 subjects (four men, 29 women, BMI 35.6 AE 4.0 (29.9 ± 43.5) kgam 2 and 43.1AE 6.1 (29 ± 54) y were excluded from the study. The ®nal study population consisted of 72 obese subjects (13 men, 59 women) with the mean BMI and age of 35.9 AE 3.9 (31.2 ± 43.4) kgam 2 and 43.4 AE 6.0 (24 ± 57) y, respectively.
Methods
All measurements were done after an overnight fast using standardized methods and were performed at the beginning (baseline), and at 3, 6, 12 and 24 months. Weight was measured after voiding, and BMI was calculated (BMI weight (kg)aheight (m 2 )). Waist circumference was measured midway between the lateral lower rib margin and the iliac crest. Hip circumference was measured at the levels of the major trochanters through the pubic symphysis. Waist ± hip ratio (WHR) was calculated (WHR waist circumferenceahip circumference). Body composition, ie the amount of FM and FFM, was determined by a bioelectrical impedance method (RJL Systems, Detroit, USA), and the ratio of FM to FFM (FMaFFM) was calculated.
REE was measured by indirect calorimeter (Deltatrac, TM Datex, Helsinki, Finland) using a computerized¯ow-through, canopy-gas analyser system, which was calibrated with the precision gas mixture before each measurement. Brie¯y, 40 l airamin was suctioned through the canopy, which was placed over the head of the patient. Samples of inspired and expired air were analysed for the differences of oxygen concentration by using a paramagnetic differential oxygen sensor and differences in carbon dioxide by using an infrared carbon dioxide analyser. Signals from the gas analysers were processed by the computer; and oxygen consumption ( VO 2 ), carbon dioxide production ( VCO 2 ) and respiratory quotient were calculated once a minute for 30 min. For each set of data the ®rst 10 min were discarded and the mean value of the data for the remaining 20 min was used in the calculations. REE (calamin) was calculated according to Ferrannini 12 and was expressed as kcaladay. Urine was collected for 12 h between 20.00 and 08.00 h and urinary nitrogen concentration was analysed by the automated Kjeldahl method. When samples were not available (at baseline n 12, at 12 months n 2, at 24 months n 1), a value of 7.6 mgaml (11 ga24 h) was used as an estimate of the urinary excretion of nitrogen in the calculation of REE. REE was adjusted by linear regression 13 for the variation in its main determinant, FFM. 5, 6 The adjusted REE (adREE) was calculated as the group mean REE plus the measured REE (individual value for each subject) minus the predicted REE (generated from the multiple regression analysis). Accordingly, the following equations were used (adREE and REE in kcal, FFM in kg): 
Procedure
In the ®rst year, the study programme included a 4 week lead-in-period including hypocaloric diet and a placebo with a single-blind bases (ie the subjects were not told that they all received placebo). After the leadin, the study was a double-blind and all subjects were randomized to receive either orlistat (120 mg t.i.d., n 36) or placebo (n 36) for 52 weeks. At the end of the ®rst year, the subjects were re-randomized, without breaking the blind, to receive either the orlistat (120 mg t.i.d., n 36) or placebo (n 36) during the second year. Accordingly, four groups were formed: orlistat during the ®rst and second year (OO, n 19), orlistat during the ®rst and placebo during the second (OP, n 17), placebo during the ®rst and orlistat during the second (PO, n 17), and placebo during the ®rst and second year (PP, n 19).
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At the beginning of the ®rst year, the subjects were counselled on the reduced energy intake by the dietician and the counselling was continued throughout the study. Prescribed energy intakes were based upon an estimate of each subject's initial maintenance energy needs (ie calculated from the subject's estimated basal metabolic rate according to the WHO formula) and were multiplied by 1.3 to estimate the total daily energy expenditure.
14 From the estimated total energy expenditure, 600 kcaladay was subtracted to obtain a mildly hypoenergetic diet (not less than 1200 kcala day) to cause a weight loss of 0.25 ± 0.5 kgaweek. The composition of the diet was nutritionally balanced with 30% of energy as fat, 50% as carbohydrate, 20% as protein, and a maximum of 300 mgaday cholesterol. Alcohol consumption was limited to no more than 150 g of alcohol per week. The diet was distributed into three main meals with a low-fat snack, if desired. The diet was adjusted after 6 months (ie caloric intake reduced by additional 300 kcaladay, however, not to lower than 1000 kcaladay) to compensate for the reduced caloric requirements following weight loss.
The purpose of the second year of the study was to assess the ability of orlistat to maintain body weight loss and prevent weight regain. Therefore, at the beginning of the second year, the subjects were prescribed a weight maintenance diet. The subjects who had lost less than 3 kg during the last 2 months were considered to be relatively weight stable, and were not advised to have further dietary adjustment. The subjects who had lost 3 kg or more during this time period were considered to be continuing to lose weight on the current diet and were prescribed energy intake equal to their estimated actual total daily energy expenditure minus 10%.
Statistical analyses
Data were analysed using the SPSS for Windows statistics programme, version 6.1.4 (SPSS, Chicago, USA). The subjects with the complete set of data for 2 y were included in the analyses. The data was analysed also by intention to treat, but since the results were practically the same, for clarity, only the completers of the study were included in the ®nal analyses. Student's t-test, chi-square test, univariate analysis of variance (one-way ANOVA) and Tukey's b-test test were used to evaluate the differences among the groups. Time-related changes among the groups were analysed using the multivariate analysis of variance for repeated measurements (MANOVA). The results are expressed as mean AE s.d., unless otherwise speci®ed. The P-value 0.05 was used as a criterion for statistical signi®cance.
Results
Subjects receiving orlistat or placebo during the ®rst year (ie the weight-reduction period) did not differ in age (42.9AE 6.4 vs 44.4 AE 6.4 y), body size, body composition or energy expenditure at the beginning of the study (Table 1) . During the ®rst year, weight, BMI, waist and hip circumferences, FFM, FM, REE and adREE decreased signi®cantly in both groups (Table 1) . Similarly, FMaFFM, WHR and percentage of body fat (FM%) (P`0.001) also decreased. The decrements in weight, BMI, waist and hip circumferences, FM (Table 1) , FMaFFM (P 0.02) and FM% (P 0.05) were greater in the subjects receiving orlistat than in those on placebo. The changes in FFM, REE, adREE (Table 1 ) and WHR (P 0.36) were similar in both groups.
The results of the second year (ie the weightmaintenance period) were analysed in four groups. The groups were formed according to the treatment during the ®rst and second year: orlistat for 2 y (OO), orlistat during the ®rst and placebo during the second year (OP), placebo during the ®rst and orlistat during (Table 2) , FM% and FMaFFM generally increased (P`0.01), whereas REE (P 0.31), adREE (P 0.34) ( Table 2 ) and WHR (P 0.25) did not change. Among the groups the changes in weight, BMI, waist and hip circumferences, FM (Table 2) , FM% (P 0.009) and FMaFFM (P 0.004) were different and were further analysed by comparing the orlistat-treated groups (OO, OP, PO) with the placebo group (PP). Smaller increases or even minor decreases were observed in the PO group as compared with the PP in weight (P 0.03), BMI (P 0.02), hip circumference (P 0.04), FM (P 0.01), FM% (P 0.02) and FMaFFM (P 0.02). The other groups did not differ signi®cantly from the PP group. Similarly, the 2 y changes in weight (P 0.02), BMI (P 0.02), hip circumference (P 0.05), FM (P 0.009), FM% (P 0.05) and FMaFFM (P 0.008) were different among the four groups. Instead, the differences among the four groups were not signi®cant in waist circumference (P 0.08), WHR (P 0.98), FFM (P 0.51), REE (P 0.20) and adREE (P 0.37). As compared to those on placebo for 2 y (PP), the subjects on orlistat for 1 or 2 y (OP, PO, OO) had signi®cantly greater decrements in weight (OP P 0.03, PO P 0.02, OO P 0.02), BMI (OP P 0.04, PO P 0.02, OO P 0.02), hip circumference (OO P 0.02), FM (PO P 0.02, OO P 0.006), FM% (PO P 0.047, OO P 0.02) and FMaFFM (PO P 0.03, OO P 0.004). The overall changes in body weight as expressed as the changes in body composition during the 2 y of treatment in each treatment group are presented in Figure 1 .
Discussion
In line with earlier reports, 11,15 ± 17 the ef®cacy of orlistat in the weight reduction was seen in the present study. The important new ®nding was that, despite the greater weight loss, the changes in FFM were similar in the orlistat and placebo groups. This implies that the body mass lost during the orlistat treatment was preferably fat, as could also be seen both as the absolute and percentage amount of fat lost as well as as the change in the ratio of FM to FFM. A similar observation was reported earlier by Drent and coworkers, 18 who during the short-term trial (12 weeks) treated subjects with very high doses (360 mg t.i.d.) of orlistat. To our knowledge our study is, however, the ®rst to report this during the long-term trial with the recommended dose (120 mg tid) of orlistat.
The present study shows that weight reduction achieved during the orlistat treatment is not associated with untoward changes in body composition, and the maintenance of FFM could promote safe weight loss. Whether orlistat itself has a particular effect on body composition or whether it is a consequence of the greater weight reduction achieved during the orlistat treatment cannot be concluded on the basis of the present study. However, the maintenance of FFM during weight reduction could help to sustain the Table 2 Anthropometric measurements during the second year of the study in four treatment groups: orlistat for 2 y (OO, n 19), orlistat during the ®rst and placebo during the second year (OP, n 17), placebo during the ®rst and orlistat during the second year (PO, n 17), and placebo for 2 y (PP, n 19) Figure 1 The changes (mean AE s.e.) of body weight as expressed as the changes of body fat and fat-free mass during 2 y of the study in four treatment groups: placebo for 2 y (PP), orlistat during the ®rst and placebo during the second year (OP) placebo during the ®rst and orlistat during the second year (PO) and orlistat for 2 y (OO). The differences among the groups (oneway ANOVA) were: weight, P 0.07, fat mass, P 0.03; fat-free mass, P 0.57. The between-group comparisons (Tukey's b-test) for fat mass were: PO vs PP P`0.05; OO vs PP, P`0.05.
Body composition, energy expenditure and orlistat L Karhunen et al reduced weight, which is admittedly dif®cult. 19, 20 In the present study, FFM in relation to the lost FM was maintained best among those on orlistat for 2 y; these subjects lost during this time period almost six times more FM than FFM as compared to those on placebo for the same time. The ®nding was similar also among the subjects on placebo during the ®rst and on orlistat during the second year. Interestingly, practically no weight regain occurred in this group during the second year of the study, indicating the bene®t of orlistat on the maintenance of reduced weight. This was in accordance with the recent report by Hill and coworkers, 21 which shows that after conventional dieting those on orlistat (120 mg t.i.d.) regained less weight than did those on placebo.
As could be expected on the basis of several previous studies, 8, 22, 23 signi®cant decrease occurred in REE during weight reduction. However, despite a greater weight loss in the orlistat group, the decrease in REE was not signi®cantly different in the orlistat and placebo groups. The ®nding can be ascribed to the fact that FFM in relation to the lost weight was maintained better in the orlistat group. The maintenance of FFM and consequently of REE is important since, by accounting for 60 ± 70% of total energy expenditure, 4 even minor changes in REE could affect energy regulation. Reduced REE after weight reduction could, in turn, slow down weight loss and contribute to a positive energy balance and weight regain. 24 Furthermore, the orlistat treatment did not seem to affect REE regardless of FFM, either, since no signi®cant differences were observed between the orlistat-and placebo-treated subjects in REE when the differences in FFM were taken into account (ie adREE).
In accordance with the greater weight loss, the treatment with orlistat was associated with the greater reductions of waist and hip circumferences. Instead, WHR did not change differently in the orlistat and placebo groups, implying that the greater decreases of waist and hip circumferences in the orlistat group could be ascribed to the greater loss of FM in general. Thus, as expressed by WHR, orlistat did not seem to have a particular effect on the distribution of the lost fat.
The bioelectrical impedance was used to measure body composition. Although the validity of this method in the measurement of body composition in obese humans has been criticized, 25 its usefulness in assessing the changes in body composition has been documented. 26, 27 Furthermore, we also have validated this method by measuring body composition by bioelectrical impedance (RJL Systems, Detroit, USA) and the dual-energy X-ray absorptiometry (Lunar DPX, Lunar Radiation Corp, Madison, WI) in obese people and found strong positive correlations between these two methods (r 0.84 for FFM and r 0.91 for FM, n 45, P Rissanen, unpublished data).
Finally, it could be argued that the bene®cial effect of orlistat on body weight and composition would not have been reached without the concurrent appropriate diet. This was seen most obviously among those on placebo (ie diet only) during the ®rst and on orlistat during the second year of the study. After learning the principles of hypoenergetic diet for weight reduction, they could bene®t from the orlistat and maintain their reduced weight.
In conclusion, orlistat is effective as a therapy for long-term weight control used together with a mildly hypocaloric balanced diet. In addition to better weight loss and maintenance of reduced weight, weight reduction achieved with orlistat treatment is associated with bene®cial changes in body composition, ie fat massafat-free mass ratio, but not with excess decrease in resting energy expenditure as compared to that achieved during the placebo treatment with dietary therapy alone.
